Evidence map›Paper›PMID 21613617›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2011

MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells.

Courtney L Erskine, Christopher J Krco, Karen E Hedin, Nancy D Borson, Kimberly R Kalli, Marshall D Behrens, Sabrina M Heman-Ackah, Eric von Hofe, Peter J Wettstein, Mansour Mohamadzadeh and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Ebola Vaccine: How Far are we?Journal of clinical and diagnostic research : JCDR · 2017
    Review
  4. Recombinant house dust mite allergens.Methods (San Diego, Calif.) · 2014
    Article
  5. Review
  6. Activation of B cells by a dendritic cell-targeted oral vaccine.Current pharmaceutical biotechnology · 2013
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Courtney L ErskineDepartment of Immunology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Christopher J Krco
Karen E Hedin
Nancy D Borson
Kimberly R Kalli
Marshall D Behrens
Sabrina M Heman-Ackah
Eric von Hofe
Peter J Wettstein
Mansour Mohamadzadeh
Keith L Knutson
Mayo Clinic · USMayo Clinic in Arizona · USAntigen Express (United States) · USNorthwestern University · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
CXCR4 CHEMOKINE RECEPTOR REGULATION OF ERK MAP KINASER01GM059763 · NIGMS · MAYO CLINIC ROCHESTER · PI HEDIN, KAREN E. · 1999 to 2015
$4.1M
Ex vivo expansion of HER-2/neu specific T helper cellsK01CA100764 · NCI · UNIVERSITY OF WASHINGTON · PI KNUTSON, KEITH L. · 2004 to 2008
$742k
NCI NIH HHS K01 CA100764NCI NIH HHS K01-CA100764NCI NIH HHS N01 CA015083NCI NIH HHS P01-CA015083NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS P50-CA136393NIGMS NIH HHS R01 GM059763
6 · The paper itself

Abstract

CD4 Th cells are critical to the development of coordinated immune responses to infections and tumors. Th cells are activated through interactions of the TCR with MHC class II complexed with peptide. T cell activation is dependent on the density of MHC peptide complexes as well as the duration of interaction of the TCR with APCs. In this study, we sought to determine whether MHC class II peptides could be modified with amino acid sequences that facilitated uptake and presentation with the goal of improving Th cell activation in vitro and in vivo. A model epitope derived from the murine folate receptor α, a self- and tumor Ag, was modified at its carboxyl terminus with the invariant chain-derived Ii-Key peptide and at its N terminus with a peptide that enhances uptake of Ag by APC. Modification of a peptide resulted in enhanced generation of high-avidity murine folate receptor α T cells that persisted in vivo and homed to sites of Ag deposition. The nesting approach was epitope and species independent and specifically excluded expansion of CD4 regulatory T cells. The resulting Th cells were therapeutic, enhanced in vivo helper activity and had an increased ability to resist tolerizing immune microenvironments. In addition to improved immunoadjuvants, this epitope modification strategy may be useful for enhancing ex vivo and in vivo generation of Th cells for preventing and treating diseases.

Indexed as

Amino Acid SequenceAnimalsCell AdhesionCell DifferentiationCell Line, TumorCell MovementDendritic CellsEpitopes, T-LymphocyteFemaleFolate Receptor 1Histocompatibility Antigens Class IIHumansMiceMice, Inbred C57BLMice, TransgenicMolecular Sequence DataEpitopes, T-LymphocyteFolate Receptor 1Histocompatibility Antigens Class IIPeptides

Identifiers

PMID21613617
PMCPMC3119756
OpenAlexW2150611231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.